drugset / Trial / NCT02255565

Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study

NCT02255565 ↗

Phase 4 Completed 36 enrolled Seattle Children's Hospital Pfizer · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to determine whether Quillivant XR is effective in the treatment of ADHD in children with Autism Spectrum Disorder (ASD).

Timeline

Start
2014-09
Primary completion
2016-09
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylphenidate Small molecule 10 mg Oral
Subject Methylphenidate Small molecule 20 mg Oral
Subject Methylphenidate Small molecule 40 mg Oral